Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Reports Declining Revenues, Increased Losses in Q2 of FY2004

NEW YORK, March 16 (GenomeWeb News) - Accelr8 Technology today reported growing losses and shrinking revenues for the second quarter of its fiscal year 2004.

 

The company booked $153,000 in revenues for the quarter, which ended Jan. 31, down from $202,000 during the same period a year ago.

 

R&D expenses stayed essentially flat at $138,000, compared to $136,000 during the same quarter last year.

 

Losses amounted to $372,000, or $.04 per share, up from $281,000, or $.03 per share, during the year-ago period.

 

The company did not state its cash or cash equivalents.

 

Accelr8, of Denver, also said that it expects Schott Nexterion to become the exclusive outsource manufacturer and marketer of its OptArray products this fall.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.